Patents Assigned to Summit Corporation PLC
-
Patent number: 9492433Abstract: This invention relates to pharmaceutical compositions comprising 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole (C1100), to processes for preparing the compositions, and to various therapeutic uses of the combinations. Also provided is a method of treatment of Duchenne muscular dystrophy or Becker muscular dystrophy using the compositions.Type: GrantFiled: November 10, 2014Date of Patent: November 15, 2016Assignee: Summit Corporation PlcInventors: Jonathon Mark Tinsley, Neil Robinson
-
Publication number: 20160151341Abstract: Described are compositions comprising imino sugar acids for the treatment of energy utilization disease (e.g. metabolic syndrome, including any disease or disorder associated therewith, for example central obesity, elevated levels of triglycerides and diabetes, including type 1 diabetes, type 2 diabetes and insulin resistance), processes for producing said compositions from various plant sources, together with various products, compounds, compositions, medical uses and methods based thereon.Type: ApplicationFiled: December 18, 2015Publication date: June 2, 2016Applicant: Summit Corporation PLCInventors: Robert James NASH, Francis Xavier WILSON, Graeme HORNE
-
Publication number: 20150209340Abstract: Disclosed are compounds of formula (I): and pharmaceutically acceptable N-oxides, salts, hydrates, solvates, complexes, bioisosteres, metabolites, and prodrugs thereof, which are of use in the treatment of infection with, and diseases caused by, Clostridium difficile.Type: ApplicationFiled: February 12, 2015Publication date: July 30, 2015Applicant: Summit Corporation PlcInventors: Peter David Johnson, Richard John Vickers, Francis Xavier Wilson, Colin Richard Dorgan, Lauren Jayne Sudlow, Stephen Paul Wren, Renate Maria van Well
-
Patent number: 8987308Abstract: Disclosed are compounds of formula (I): or a pharmaceutically acceptable N-oxide, salt, hydrate, solvate, complex, bioisostere, metabolite or prodrug thereof, which are of use in the treatment of infection with, and diseases caused by, Clostridium difficile.Type: GrantFiled: November 30, 2012Date of Patent: March 24, 2015Assignee: Summit Corporation PlcInventors: Peter David Johnson, Richard John Vickers, Francis Xavier Wilson, Colin Richard Dorgan, Lauren Jayne Sudlow, Stephen Paul Wren, Renate van Well
-
Patent number: 8975416Abstract: Disclosed are compounds of formula (I), which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by, Clostridium difficile.Type: GrantFiled: December 1, 2009Date of Patent: March 10, 2015Assignee: Summit Corporation PLCInventors: Paul James Davis, Olivier De Moor, Colin Richard Dorgan, Peter David Johnson, Alan Geoffrey Roach, Richard Storer, Richard John Vickers, Francis Xavier Wilson, Graham Michael Wynne
-
Publication number: 20140018320Abstract: There are disclosed compound of Formula (1): A1, A2, A3 and A4 which may be the same or different, represent N or CR1, X is a divalent group selected from O, S(O)n, C?W, NR4, NC(?O)R5 and CR6R7, W is O, S, NR20, Y is N or CR8, one of R4, R5, R6, R8, R9 and NR20 represents -L-R3, in which L is a single bond or a linker group, additionally, R1, R3-R9, which may be the same or different, independently represent hydrogen or a substituent and R20 represents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO2, NR30R31, in which R30 and R31, which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of R30 and R31 may represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent paiType: ApplicationFiled: July 11, 2013Publication date: January 16, 2014Applicant: Summit Corporation PLCInventors: GRAHAM MICHAEL WYNNE, STEPHEN PAUL WREN, PETER DAVID JOHNSON, PAUL DAMIEN PRICE, OLIVIER DE MOOR, GARY NUGENT, RICHARD STORER, RICHARD JOSEPH PYE, COLIN RICHARD DORGAN
-
Patent number: 8518980Abstract: There are disclosed compound of Formula (1): A1, A2, A3 and A4 which may be the same or different, represent N or CR1, X is a divalent group selected from O, S(O)n, C?W, NR4, NC(?O)R5 and CR6R7, W is O, S, NR20, Y is N or CR8, one of R4, R5, R6, R8, R9 and NR20 represents -L-R3, in which L is a single bond or a linker group, additionally, R1, R3-R9, which may be the same or different, independently represent hydrogen or a substituent and R20 represents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO2, NR30R31, in which R30 and R31, which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of R30 and R31 may represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent paiType: GrantFiled: February 9, 2007Date of Patent: August 27, 2013Assignee: Summit Corporation PLCInventors: Graham Michael Wynne, Stephen Paul Wren, Peter David Johnson, Paul Damien Price, Olivier De Moor, Gary Nugent, Richard Storer, Richard Joseph Pye, Colin Richard Dorgan
-
Patent number: 8501713Abstract: Combinations comprising (or consisting essentially of) one or more compounds of formula (1) with one or more ancillary agents, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia using the combinations.Type: GrantFiled: August 1, 2008Date of Patent: August 6, 2013Assignee: Summit Corporation PLCInventors: Graham Michael Wynne, Stephen Paul Wren, Peter David Johnson, Paul Damien Price, Olivier De Moor, Gary Nugent, Richard Storer, Richard Joseph Pye, Colin Richard Dorgan
-
Publication number: 20120149741Abstract: There are provided compounds of Formula (I) wherein three of A1, A2, A3, and A4 represent CH and one of A1, A2, A3, and A4 represents CR1; R1 represents SO2R2 or NHCOR2 wherein R2 represents C1-C6 alkyl optionally substituted by one or more halogen, hydroxyl or alkoxy groups; R9 represents C6-C10 aryl; or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 14, 2008Publication date: June 14, 2012Applicants: Biomarin IGA Limited, Summit Corporation PLCInventor: Graham Michael WYNNE
-
Patent number: 8138351Abstract: Provided is a process for the preparation of 5-(ethylsulfonyl)-2-(naphthalen-2-yl) benzo[d] oxazole useful in the treatment of Duchenne muscular dystrophy.Type: GrantFiled: August 14, 2008Date of Patent: March 20, 2012Assignee: Summit Corporation PLCInventors: Graham Michael Wynne, Alexander Charles Weymouth-Wilson, Robert Clarkson, Renate Van Well, Stephen Paul Wren, Olivier De Moor
-
Publication number: 20110237538Abstract: Described are various compounds, in particular iminosugars, and methods for the treatment of proteostatic diseases, in particular lysosomal storage disorders. The compound may be a pharmacoperone of an enzyme selected from: (a) Acid alpha-glucosidase; (b) Acid beta-glucosidase; (c) glucocerebrosidase; (d) alpha-Galactosidase A; (e) Acid beta-galactosidase; (f) beta-Hexosaminidase A; (g) beta-Hexosaminidase B; (h) Acid sphingomyelinase; (i) Galactocerebrosidase; (j) Acid ceramidase; (k) Arylsulfatase A; (l) alpha-L-Iduronidase; (m) Iduronate-2-sulfatase; (n) Heparan N-sulfatase; (o) alpha-N-Acetylglucosaminidase; (p) Acetyl-CoA: alpha-glucosaminide N-acetyltransferase; (q) N-Acetylglucosamine-6-sulfate sulfatase; (r) N-Acetylgalactosamine-6-sulfate sulfatase; (s) Acid beta-galactosidase; (t) Arylsulfatase B; (u) beta-Glucuronidase; (v) Acid alpha-mannosidase; (w) Acid beta-mannosidase; (x) Acid alpha-L-fucosidase; (y) Sialidase; and (z) alpha-N-acetylgalactosaminidase.Type: ApplicationFiled: August 4, 2009Publication date: September 29, 2011Applicant: SUMMIT CORPORATION PLCInventors: Olivier De Moor, Graeme Horne, Penny Jane Middleton, Frank Schroer, Stephen Paul Wren, Maria Ines Passos Eleuterio, Renate Van Well, Colin Richard Dorgan, Francis Xavier Wilson, Robert Nash, Richard Storer, Graham Michael Wynne, Alan Geoffrey Roach, Akane Kawamura, Jonathon Mark Tinsley
-
Publication number: 20110195929Abstract: Described are various compounds and methods for the treatment of flaviviral infections. In particular, alkaloids and imino sugars in arabinose and/or lyxose stereochemical configuration with antiflaviviral activity are described.Type: ApplicationFiled: August 4, 2009Publication date: August 11, 2011Applicant: SUMMIT CORPORATION PLCInventors: Olivier De Moor, Graeme Horne, Penny Jane Middleton, Frank Schroer, Stephen Paul Wren, Maria Ines Passos Eleuterio, Renate Van Well, Colin Richard Dorgan, Francis Xavier Wilson, Robert Nash, Richard Storer, Graham Michael Wynne, Alan Geoffrey Roach, Akane Kawamura, Jonathon Mark Tinsley
-
Publication number: 20110015226Abstract: Described are compositions comprising imino sugar acids for the treatment of energy utilization disease (e.g. metabolic syndrome, including any disease or disorder associated therewith, for example central obesity, elevated levels of triglycerides and diabetes, including type 1 diabetes, type 2 diabetes and insulin resistance), processes for producing said compositions from various plant sources, together with various products, compounds, compositions, medical uses and methods based thereon.Type: ApplicationFiled: February 17, 2009Publication date: January 20, 2011Applicant: SUMMIT CORPORATION PLCInventors: Robert James Nash, Francis Xavier Wilson, Graeme Horne